Skip to main content
Premium Trial:

Request an Annual Quote

SeqLL Withdraws Plans for $8M IPO

NEW YORK – Sequencing instrument and services firm SeqLL last week halted plans for an $8 million initial public offering.

In an April 24 filing with the US Securities and Exchange Commission, CFO John Kennedy requested withdrawal of SeqLL's Form S-1 registration statement, initially filed April 2019. The firm had planned to offer approximately 1.4 million shares of common stock at an IPO price between $5.40 and $6.40 per share. It would have traded on the Nasdaq under ticker symbol "SQL." WallachBeth Capital was the sole bookrunning manager for the offering.

Founded in 2013, the Woburn, Massachusetts-based firm is attempting to continue offering sequencing technology developed by Helicos BioSciences.

The firm disclosed to the SEC that its revenues were $779,068 for fiscal year 2018 and $257,117 for the first half of 2019. SeqLL had planned to use the IPO proceeds to expand its commercial operations and address a "lack of marketing" that had constrained sales, the firm said in its registration statement.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.